TWI592406B - 嘧啶酪氨酸激酶抑制劑 - Google Patents

嘧啶酪氨酸激酶抑制劑 Download PDF

Info

Publication number
TWI592406B
TWI592406B TW102120447A TW102120447A TWI592406B TW I592406 B TWI592406 B TW I592406B TW 102120447 A TW102120447 A TW 102120447A TW 102120447 A TW102120447 A TW 102120447A TW I592406 B TWI592406 B TW I592406B
Authority
TW
Taiwan
Prior art keywords
compound
amino
mixture
oxo
chloro
Prior art date
Application number
TW102120447A
Other languages
English (en)
Chinese (zh)
Other versions
TW201410668A (zh
Inventor
布萊恩Ｔ 哈柏金
派翠克 科隆
提摩西Ｒ 查
崔西Ｊ 傑金斯
席衛 凱
翔林 辛
羅斯Ａ 米勒
安德魯 湯普森
Original Assignee
百健Ｍａ公司
桑西斯醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 百健Ｍａ公司, 桑西斯醫藥公司 filed Critical 百健Ｍａ公司
Publication of TW201410668A publication Critical patent/TW201410668A/zh
Application granted granted Critical
Publication of TWI592406B publication Critical patent/TWI592406B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW102120447A 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑 TWI592406B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08

Publications (2)

Publication Number Publication Date
TW201410668A TW201410668A (zh) 2014-03-16
TWI592406B true TWI592406B (zh) 2017-07-21

Family

ID=49712704

Family Applications (3)

Application Number Title Priority Date Filing Date
TW102120447A TWI592406B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW110102365A TWI792158B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW106116775A TWI719209B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110102365A TWI792158B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW106116775A TWI719209B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑

Country Status (30)

Country Link
US (6) US9394277B2 (enExample)
EP (3) EP3753934A1 (enExample)
JP (6) JP6214643B2 (enExample)
KR (4) KR20220154850A (enExample)
CN (3) CN113549055A (enExample)
AR (1) AR091273A1 (enExample)
AU (5) AU2013271407B2 (enExample)
BR (2) BR112014030655B1 (enExample)
CA (2) CA2875799C (enExample)
CY (1) CY1120638T1 (enExample)
DK (1) DK2858499T3 (enExample)
EA (2) EA027823B1 (enExample)
ES (2) ES2834333T3 (enExample)
HR (1) HRP20181294T1 (enExample)
HU (1) HUE039897T2 (enExample)
IL (2) IL235938B (enExample)
IN (1) IN2014DN10576A (enExample)
LT (1) LT2858499T (enExample)
MX (2) MX385593B (enExample)
NZ (1) NZ702715A (enExample)
PH (2) PH12018501463B1 (enExample)
PL (1) PL2858499T3 (enExample)
PT (1) PT2858499T (enExample)
RS (1) RS57978B1 (enExample)
SG (2) SG10201708535UA (enExample)
SI (1) SI2858499T1 (enExample)
SM (1) SMT201800442T1 (enExample)
TW (3) TWI592406B (enExample)
WO (1) WO2013185084A1 (enExample)
ZA (1) ZA201409255B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719209B (zh) * 2012-06-08 2021-02-21 美商百健Ｍａ公司 嘧啶酪氨酸激酶抑制劑

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI711610B (zh) * 2009-09-04 2020-12-01 美商百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
US9353087B2 (en) * 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
US9809577B2 (en) * 2013-12-11 2017-11-07 Biogen Ma Inc. Biaryl inhibitors of Bruton's tyrosine kinase
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
HUE050706T2 (hu) 2014-10-24 2020-12-28 Bristol Myers Squibb Co Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként
CN110049976A (zh) * 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
KR102545594B1 (ko) 2018-07-31 2023-06-21 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
EP4448523A1 (en) 2021-12-14 2024-10-23 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
CZ20023033A3 (cs) 2000-03-17 2003-01-15 Bristol-Myers Squibb Pharma Company Deriváty cyklických beta-aminokyselin jako inhibitory matrixových metaloproteáz a TNF-alfa
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
EA006153B1 (ru) 2000-06-26 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US20050143372A1 (en) * 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
WO2003037898A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
EP1778298A4 (en) * 2004-04-01 2010-03-31 Univ Pennsylvania LIPOPROTEIN-NANO PLATFORMS
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
US7528138B2 (en) * 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
CN101378807A (zh) * 2005-12-21 2009-03-04 先灵公司 H3拮抗剂/反相激动剂与食欲抑制剂的组合
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
EP2059305A2 (en) 2006-07-26 2009-05-20 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
EP2068849A2 (en) * 2006-09-11 2009-06-17 CGI Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2009134891A2 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
MX2009009417A (es) * 2007-03-02 2009-09-11 Schering Corp Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
US8093239B2 (en) 2007-06-01 2012-01-10 Glaxosmithkline Llc Imidazopyridine kinase inhibitors
WO2009098144A1 (en) 2008-02-05 2009-08-13 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
CN102325753B (zh) * 2008-12-19 2014-09-10 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
EP2379559B1 (en) * 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
WO2010136422A1 (de) 2009-05-25 2010-12-02 Sandoz Ag Verfahren zur herstellung von ceftobiprol medocaril
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
TWI711610B (zh) 2009-09-04 2020-12-01 美商百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
US8685880B2 (en) 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9809577B2 (en) 2013-12-11 2017-11-07 Biogen Ma Inc. Biaryl inhibitors of Bruton's tyrosine kinase
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
CN110049976A (zh) * 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719209B (zh) * 2012-06-08 2021-02-21 美商百健Ｍａ公司 嘧啶酪氨酸激酶抑制劑

Also Published As

Publication number Publication date
NZ702715A (en) 2016-11-25
EP2858499A1 (en) 2015-04-15
AU2019203476A1 (en) 2019-06-06
KR20220154850A (ko) 2022-11-22
TWI792158B (zh) 2023-02-11
JP2015518903A (ja) 2015-07-06
JP2023052415A (ja) 2023-04-11
IL235938A0 (en) 2015-02-01
CY1120638T1 (el) 2019-12-11
ES2834333T3 (es) 2021-06-17
JP2021073299A (ja) 2021-05-13
AU2022275504A1 (en) 2023-01-05
HRP20181294T1 (hr) 2018-10-05
IL277951A (en) 2020-11-30
BR122021002178B1 (pt) 2022-03-22
EA201790418A1 (ru) 2017-11-30
SI2858499T1 (sl) 2018-10-30
EP2858499A4 (en) 2016-01-20
TW201805279A (zh) 2018-02-16
CA2875799C (en) 2021-03-23
CA3108186A1 (en) 2013-12-12
EA027823B1 (ru) 2017-09-29
MX385593B (es) 2025-03-18
CA2875799A1 (en) 2013-12-12
JP6214643B2 (ja) 2017-10-18
AR091273A1 (es) 2015-01-21
KR20150036020A (ko) 2015-04-07
US9944622B2 (en) 2018-04-17
CN104540385B (zh) 2018-06-05
CN104540385A (zh) 2015-04-22
ZA201409255B (en) 2015-12-23
PL2858499T3 (pl) 2019-03-29
TWI719209B (zh) 2021-02-21
AU2019203476B2 (en) 2021-01-28
HK1209284A1 (en) 2016-04-01
BR112014030655B1 (pt) 2021-04-20
EP3385263B1 (en) 2020-07-22
PH12014502699B1 (en) 2015-02-02
EA201492056A1 (ru) 2015-05-29
BR112014030655A2 (pt) 2017-06-27
EP3385263A1 (en) 2018-10-10
EP2858499B1 (en) 2018-05-16
US20230174511A1 (en) 2023-06-08
KR20210072139A (ko) 2021-06-16
AU2021202412A1 (en) 2021-05-20
WO2013185084A1 (en) 2013-12-12
IL235938B (en) 2020-10-29
JP2019077728A (ja) 2019-05-23
US20160304494A1 (en) 2016-10-20
PH12014502699A1 (en) 2015-02-02
PH12018501463B1 (en) 2024-03-27
HUE039897T2 (hu) 2019-02-28
JP2017193583A (ja) 2017-10-26
SG10201708535UA (en) 2017-11-29
MX2014015044A (es) 2015-09-22
US10618887B2 (en) 2020-04-14
EP3753934A1 (en) 2020-12-23
MX2019003618A (es) 2019-07-18
ES2684268T3 (es) 2018-10-02
KR20200043497A (ko) 2020-04-27
JP2021073298A (ja) 2021-05-13
US20190047986A1 (en) 2019-02-14
IN2014DN10576A (enExample) 2015-08-28
AU2013271407B2 (en) 2016-12-08
US9394277B2 (en) 2016-07-19
PH12018501463A1 (en) 2019-03-04
US20240417389A1 (en) 2024-12-19
PT2858499T (pt) 2018-10-24
LT2858499T (lt) 2018-09-10
AU2017201536B2 (en) 2019-03-07
DK2858499T3 (en) 2018-08-20
KR102468430B1 (ko) 2022-11-21
RS57978B1 (sr) 2019-01-31
TW201410668A (zh) 2014-03-16
AU2013271407A1 (en) 2015-01-22
AU2017201536A1 (en) 2017-03-23
TW202142535A (zh) 2021-11-16
BR112014030655A8 (pt) 2018-01-02
US20150158843A1 (en) 2015-06-11
US20210017155A1 (en) 2021-01-21
CN113549055A (zh) 2021-10-26
CN109305959B (zh) 2022-02-08
MX363672B (es) 2019-03-29
SMT201800442T1 (it) 2018-09-13
SG11201408173WA (en) 2015-01-29
CN109305959A (zh) 2019-02-05
KR102102587B1 (ko) 2020-04-22

Similar Documents

Publication Publication Date Title
TWI592406B (zh) 嘧啶酪氨酸激酶抑制劑
HK40043767A (en) Pyrimidinyl derivatives useful as tyrosine kinase inhibitors
HK1262106A1 (en) Pyrimidinyl tyrosine kinase inhibitors
HK1262106B (en) Pyrimidinyl tyrosine kinase inhibitors
HK1209284B (zh) 嘧啶基酪氨酸激酶抑制劑

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees